Literature DB >> 35676327

Dysregulation of IL-34 ligation to SDC-1 mitigates collagen-induced arthritis.

Anja Meyer1,2, Ryan Sienes1, Brian Zanotti3, Katrien van Raemdonck1,2, Karol Palasiewicz1,2, Daniel P Mass4, Michael V Volin3, Shiva Shahrara5,6.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2022        PMID： 35676327      PMCID： PMC9424265          DOI： 10.1038/s41423-022-00886-x

Source DB:  PubMed          Journal:  Cell Mol Immunol        ISSN： 1672-7681            Impact factor:   22.096


× No keyword cloud information.
  10 in total

1.  Increased levels of interleukin 34 in serum and synovial fluid are associated with rheumatoid factor and anticyclic citrullinated peptide antibody titers in patients with rheumatoid arthritis.

Authors:  Su-Jin Moon; Yeon-Sik Hong; Ji Hyeon Ju; Seung-Ki Kwok; Sung-Hwan Park; Jun-Ki Min
Journal:  J Rheumatol       Date:  2013-09-01       Impact factor: 4.666

2.  Baseline serum interleukin-34 levels independently predict radiographic progression in patients with rheumatoid arthritis.

Authors:  Sung Hae Chang; Byoong Yong Choi; Jungbum Choi; Jong Jin Yoo; You-Jung Ha; Hyon Joung Cho; Eun Ha Kang; Yeong Wook Song; Yun Jong Lee
Journal:  Rheumatol Int       Date:  2014-06-11       Impact factor: 2.631

3.  IL-34- and M-CSF-induced macrophages switch memory T cells into Th17 cells via membrane IL-1α.

Authors:  Etienne D Foucher; Simon Blanchard; Laurence Preisser; Philippe Descamps; Norbert Ifrah; Yves Delneste; Pascale Jeannin
Journal:  Eur J Immunol       Date:  2015-01-19       Impact factor: 5.532

4.  Increased IL-6 expression on THP-1 by IL-34 stimulation up-regulated rheumatoid arthritis Th17 cells.

Authors:  Bing Wang; Yawei Tang; Xiaotong Sun; Xunli Ouyang; Han Li; Jing Wei; Yan Zhang; Xia Li
Journal:  Clin Rheumatol       Date:  2017-08-15       Impact factor: 2.980

5.  IL-34 is associated with obesity, chronic inflammation, and insulin resistance.

Authors:  Eun-Ju Chang; Seul Ki Lee; Young Sook Song; Yeon Jin Jang; Hye Soon Park; Joon Pio Hong; A Ra Ko; Dae Yeon Kim; Jong-Hyeok Kim; Yeon Ji Lee; Yoon-Suk Heo
Journal:  J Clin Endocrinol Metab       Date:  2014-04-08       Impact factor: 5.958

6.  The cut-off value for interleukin 34 as an additional potential inflammatory biomarker for the prediction of the risk of diabetic complications.

Authors:  Katarzyna Zorena; Olga Jachimowicz-Duda; Piotr Wąż
Journal:  Biomarkers       Date:  2016-02-05       Impact factor: 2.658

7.  Interleukin-34 Reprograms Glycolytic and Osteoclastic Rheumatoid Arthritis Macrophages via Syndecan 1 and Macrophage Colony-Stimulating Factor Receptor.

Authors:  Katrien Van Raemdonck; Sadiq Umar; Karol Palasiewicz; Michael V Volin; Hatem A Elshabrawy; Bianca Romay; Chandana Tetali; Azam Ahmed; M Asif Amin; Ryan K Zomorrodi; Nadera Sweiss; Shiva Shahrara
Journal:  Arthritis Rheumatol       Date:  2021-09-22       Impact factor: 10.995

8.  Effect of IL-34 on T helper 17 cell proliferation and IL-17 secretion by peripheral blood mononuclear cells from rheumatoid arthritis patients.

Authors:  Xin Li; Yimeng Lei; Ziyu Gao; Bei Zhang; Liping Xia; Jing Lu; Hui Shen
Journal:  Sci Rep       Date:  2020-12-17       Impact factor: 4.379

9.  VIS832, a novel CD138-targeting monoclonal antibody, potently induces killing of human multiple myeloma and further synergizes with IMiDs or bortezomib in vitro and in vivo.

Authors:  Tengteng Yu; Bharat Chaganty; Liang Lin; Lijie Xing; Boopathy Ramakrishnan; Kenneth Wen; Phillip A Hsieh; Andrew Wollacott; Karthik Viswanathan; Hedy Adari; Shih-Feng Cho; Yuyin Li; Hailin Chen; Wenjuan Yang; Yan Xu; Gang An; Lugui Qiu; Nikhil Munshi; Gregory Babcock; Zachary Shriver; James R Myette; Kenneth C Anderson; Yu-Tzu Tai
Journal:  Blood Cancer J       Date:  2020-11-02       Impact factor: 11.037

10.  IL-34 Actions on FOXP3+ Tregs and CD14+ Monocytes Control Human Graft Rejection.

Authors:  Séverine Bézie; Antoine Freuchet; Céline Sérazin; Apolline Salama; Nadège Vimond; Ignacio Anegon; Carole Guillonneau
Journal:  Front Immunol       Date:  2020-08-11       Impact factor: 7.561
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.